Globus Medical, Inc. (GMED) Stock Forecast
GMED analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.13 / 5 from 15 analysts
- Price target
- $100.92 average of analyst targets
- Upside to target
- +31.6% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $1.20
- 52-week range
- $60.39 – $96.82
GMED analyst ratings
15 analystsNumber of analysts at each rating.
GMED price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
GMED earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $1.20 | $1.13 | $1.26 | $1.18 | +1.4% | 13 |
| Current fiscal year (2026) | $5.00 | $4.97 | $5.05 | $3.98 | +25.6% | 14 |
| Next fiscal year (2027) | $5.39 | $5.10 | $5.62 | $5.00 | +7.8% | 13 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
GMED revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $792.5M | $776.3M | $812.9M | +3.0% | 14 |
| Current fiscal year (2026) | $3.20B | $3.18B | $3.22B | +8.9% | 14 |
| Next fiscal year (2027) | $3.39B | $3.36B | $3.44B | +6.0% | 14 |
GMED EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
GMED revenue: reported and forecast
GMED EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $1.17 | $1.19 | $1.20 | $1.20 | $1.20 | +2.3% | 9 up · 0 down |
| Current fiscal year (2026) | $4.74 | $4.98 | $5.00 | $5.00 | $5.00 | +5.4% | 13 up · 0 down |
| Next fiscal year (2027) | $5.15 | $5.36 | $5.40 | $5.40 | $5.39 | +4.7% | 12 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
GMED earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; GMED beat in 10 of 12.
What analysts expect from GMED
15 analysts cover Globus Medical; their consensus rating is buy (4.13 on a 1–5 scale, where 5 is a strong buy). The average price target is $100.92, 31.6% above the latest close of $76.71. Analysts expect earnings of $5.00 per share for 2026, +25.6% from a year earlier. For 2027 the average estimate is $5.39 per share on revenue of $3.4 billion. Globus Medical beat the EPS estimate in 10 of the last 12 quarters.
Related: GMED income statement, GMED key metrics, GMED chart. See the GMED stock overview for the latest quote and news.
GMED forecast FAQ
What is Globus Medical's price target?
The average analyst price target for Globus Medical is $100.92, 31.6% above the latest close of $76.71.
Is Globus Medical a buy, hold or sell?
Of 15 analysts covering Globus Medical, 7 rate it a strong buy, 3 a buy, 5 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Globus Medical's EPS forecast?
Analysts forecast $5.00 per share for 2026 (range $4.97 to $5.05); for 2027 the estimate is $5.39.
What is Globus Medical's revenue forecast?
The average revenue estimate for 2026 is $3.2 billion, growth of 8.9%; for 2027 it is $3.4 billion.
When does Globus Medical report earnings?
Globus Medical is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 after the market closes; the EPS estimate is $1.20.
Does Globus Medical usually beat earnings estimates?
Globus Medical reported EPS at or above the analyst estimate in 10 of the last 12 quarters.